文献速递流行病学与生物统计真实世界研究与卫生经济新药、器械与细胞基因治疗研发

全球健康2050:到本世纪中叶将过早死亡概率减半的路径

Global health 2050: the path to halving premature death by mid-century.
PubMed 文献 · Lancet · 2024-10-14

柳叶刀健康投资委员会报告提出「50 by 50」目标:到2050年各国可将70岁前死亡概率(PPD)较2019年大流行前水平减半,并设2035年中期里程碑「30 by 2035」。实现路径聚焦15个优先病种、19个干预模块和初级卫生保健系统强化,烟草控制是最重要的跨部门政策。

要点

  • 到2050年可将70岁前死亡概率较2019年水平减半,中期里程碑为2035年降低30%。
  • 路径聚焦15个优先病种:高死亡率国家优先8种传染病和孕产妇疾病,7类非传染性疾病和伤害普遍重要。
  • 烟草控制是跨部门政策中最重要的,高烟草税至关重要并应配合其他有效控烟政策。

核心结论

  • 柳叶刀健康投资委员会认为,通过聚焦健康投资,到2050年各国可将过早死亡概率(PPD)较2019年大流行前水平减半,即「50 by 50」目标,并设2035年降低30%的中期里程碑。
  • 实现「50 by 50」的路径聚焦15个优先病种,通过19个干预模块和初级卫生保健系统强化来落实。
  • 烟草控制是政府可采取的跨部门政策中最重要的,高烟草税至关重要并应配合其他有效控烟政策。

研究设计与样本

  • 本报告为柳叶刀健康投资委员会(Lancet Commission on Investing in Health)发布的全球健康2050(GH2050)报告。

主要发现

  • 过去十年,30个人口最多国家中有8个国家的PPD下降速度可在2050年前实现减半,包括孟加拉国、伊朗、坦桑尼亚和土耳其等差异较大的国家。
  • 委员会背景研究指出,大流行病导致的死亡风险持续处于异常高水平;COVID-19各国表现差异很大,疫苗可及性到紧急阶段结束时减弱但远未消除这种差异。
  • 日本等表现最佳国家的成功很大程度上归因于落实公共卫生基本原则:早期行动、隔离感染者、隔离暴露者以及为隔离或检疫者提供社会和财务支持。
  • 十年前尚无疟疾疫苗且唯一可用的结核疫苗效力低;如今已有两种部分成功的疟疾疫苗获批,三种有前景的结核疫苗候选处于后期试验。
  • 经济分析显示,可实现的死亡率下降价值很高,往往占GDP增长价值的相当大比例。

关键数值与推荐

  • 「50 by 50」目标:到2050年将PPD较2019年大流行前水平降低50%。
  • 中期里程碑「30 by 2035」:到2035年将PPD降低30%。
  • 15个优先病种:对当前高死亡率国家,8种传染病和孕产妇疾病为最高优先级;7类非传染性疾病和伤害在所有地方都重要。
  • 19个干预模块(如儿童免疫模块、心血管疾病预防和低成本广泛可及治疗模块)用于应对15个优先病种。
  • 药品可及性和可负担性通常需要四个互补组成部分:将一般预算转移重新定向为特定优先药品的专项转移(补贴);由政府(或国际)集中采购;采购足够数量以确保需要时可用;利用和加强现有公私供应链。

临床怎么用

  • 委员会结论主要针对各国政府:采取聚焦方法投资于初级卫生保健和一级医院系统强化,以更好应对15个优先病种。
  • 委员会建议通过将预算转移中相当大且递增的比例用于使15个优先病种相关的特定药品、疫苗、诊断和其他商品可及和可负担,来解决标准预算机制未能成功重新定向系统的问题。
  • 委员会认为烟草控制是跨部门政策中最重要的,高烟草税至关重要并应配合一揽子其他有效控烟政策。
  • 委员会最后结论针对发展援助界:援助应聚焦两个广泛目的,一是向资源最少国家提供直接财政和技术支持以发展卫生系统,二是资助全球公共产品。
  • 委员会指出,下次大流行中,早期行动、隔离感染者、隔离暴露者以及为隔离或检疫者提供社会和财务支持等公共卫生基本原则将有助于在等待疫苗研发和部署期间避免死亡。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Global health 2050 (GH2050), a new report from the Lancet Commission on Investing in Health, finds that dramatic improvements in human welfare are achievable by mid-century with focused health investments. By 2050, countries that choose to do so can halve their probability of premature death (PPD)—the probability of dying before age 70—from their pre-pandemic level in 2019. We call this goal “50 by 50”: a 50% reduction in PPD by 2050. The interventions for achieving “50 by 50” will also reduce morbidity and disability at all ages. Historical experience and continued scientific advance indicate that this is a feasible aspiration. Eight of the 30 most populous countries reduced their PPD over the last decade at a rate that would halve PPD before 2050, including countries as diverse as Bangladesh, Iran, Tanzania, and Turkey. These focused gains can be achieved relatively early on the pathway to full universal health coverage (UHC). The path to achieving “50 by 50” runs through control of a remarkably narrow set of just 15 conditions. For currently high mortality countries, eight infectious diseases and maternal conditions are the highest priority. Seven clusters of noncommunicable diseases and injuries are important everywhere and addressing them will prove central to achieving “50 by 50” in most countries with lower initial levels of mortality. Focused attention to health system strengthening (HSS) for primary care and first level hospitals will generate capacity to better tackle the 15 priority conditions and will be a critical step on the way to improving capacity to address all the conditions in a UHC package. Packaging interventions into 19 modules (e.g., a childhood immunization module, a module on cardiovascular disease prevention and low-cost, widely available treatment) will address the 15 priority conditions. Adopting this focused approach also invests in key areas of HSS and addresses major morbidities, such as psychiatric illness, not already covered by mortality-reducing interventions. Value for money can be assessed through a two-step process: technical cost effectiveness to assess how best to achieve module-specific goals (e.g., reduction in child mortality, reduction in cardiovascular mortality) and political evaluation of trade-offs in investing in expanding module coverage. In many countries seeking reform, standard budgetary mechanisms have failed to successfully reorient systems toward priority interventions that improve health. This mechanism of blanket budget transfers from ministries of finance to ministries of health has not been fit to support such reorientation. The Commission concluded that this problem could be addressed by directing a substantial and increasing fraction of budget transfers to making available and affordable the specific drugs, vaccines, diagnostics, and other commodities that are currently available for control of the 15 priority conditions. Drug availability and affordability will typically require four complementary components: (i) redirecting general budget transfers to line item transfers (subsidies) for specific priority drugs; (ii) centralized procurement by government (or perhaps internationally); (iii) procurement in sufficient volumes to ensure availability when needed; and (iv) use and strengthening of existing supply chains, public and private. Of the many intersectoral policies that governments can adopt to help achieve “50 by 50,” tobacco control is by far the most important, given the number of deaths caused by tobacco and the established and improving capacity of governments to implement tobacco policy. A high level of tobacco taxation is essential, and valuable in the short to medium term for public finance, and should be accompanied by a package of other effective tobacco control policies. Background research conducted for the Commission points to exceptionally high ongoing levels of mortality risk from pandemics. Country performance against COVID-19 varied greatly, although eventual vaccine availability attenuated, but far from eliminated, this variability by the end of COVID-19’s emergency phase. National implementation of public health fundamentals—early action, isolation of infected individuals, quarantining of those exposed, and social and financial support for people isolating or quarantining—accounted for much of the success of the best-performing nations, such as Japan. In the next pandemic, these fundamentals will help to avert mortality while waiting for vaccine development and deployment. The conclusions above are primarily aimed at national governments. Our final conclusion is aimed at the development assistance community. We conclude that such assistance should focus on two broad purposes. The first is to provide direct financial and technical support to countries with the least resources—to help develop health systems to better control diseases. The second is to finance global public goods, including strengthening data systems; reducing the development and spread of antimicrobial resistance; preventing and responding to pandemics; fostering global health leadership and advocacy; identifying and spreading best practices; and developing and deploying new health technologies. For both purposes, focusing efforts on the 15 priority conditions would best contribute to “50 by 50.” A decade ago, there were no malaria vaccines and the only available tuberculosis vaccine had low efficacy. Today, two partially successful malaria vaccines have been approved and three promising tuberculosis vaccine candidates are in late stage trials. These successes exemplify the enormous value in funding development of new medicines, vaccines, diagnostics, and operational research against the 15 priority conditions. The prize of “50 by 50,” with an interim milestone of “30 by 2035” (a 30% reduction in PPD by 2035), remains a prize within reach. The most efficient route is to focus resources against a narrow set of conditions and scale up financing to develop and deploy new health technologies. Our economic analyses have shown that the value of achievable mortality declines remains high and indeed is often a substantial fraction of the value of gains in gross domestic product. Today, the case is better than ever for the value of investing in health for reducing mortality and morbidity, alleviating poverty, growing economies, and improving human welfare.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Jamison DT, Summers LH, Chang AY, et al. Global health 2050: the path to halving premature death by mid-century. Lancet. 2024. PMID: 39419055. doi:10.1016/S0140-6736(24)01439-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。